Access detailed search options for content from the Clinical Journal of Oncology Nursing & Oncology Nursing Forum below.
Discover what you can learn on our survivorship online learning library. Explore over 15 resources compiled of both ONS and external content such as practice resources, courses, podcasts, websites, and more.
Discover what you can learn about breast cancer in our online learning library. Explore resources curated from ONS content and offerings, such as books, courses, clinical practice resources, and articles.
Cancers of the bladder and urinary tract affect tens of thousands of Americans every year, as one of the most prevalent cancers in the United States. Urothelial carcinoma is the predominant histological type. Explore resources related to the treatment and care of these patients.
The onboarding process is critical to ensure oncology nurses feel ready to deliver quality cancer care to people with cancer. ONS has developed orientation-based didactic courses, clinical practice resources, and other training tools to use to ensure optimal orientation for nurses new to the clinical and advanced practice roles. Whether you are working to improve your institution’s onboarding process or looking for individual resources to complement your own orientation, ONS has an option for you within the Orientation Learning Library.
Using two agents that target two different receptors more than doubles length of survival for advanced melanoma than a single agent alone, researchers reported at the 2021 American Society of Clinical Oncology annual meeting.
Patients with uveal melanoma who were treated with tebentafusp, an investigational immunotherapy, lived a median 5.7 months longer than those in comparison groups, researchers reported in study findings presented at the American Association for Cancer Research 2021 annual meeting.
Completing up to a year of pembrolizumab immunotherapy after surgical resection of stage IIB or IIC melanoma decreases patients’ risk for disease recurrence or death by 35%, according to study findings presented at the European Society for Medical Oncology 2021 annual meeting. The new findings led the U.S. Food and Drug Administration to expand its approval of pembrolizumab to use as adjuvant therapy in both adults and children aged 12 and older with early-stage melanoma.